ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

orelabrutinib

Also written as “ICP-022”, “Orelabrutinib” and “ICP-248+Orelabrutinib”.

Its studies are mostly in Lymphoma, Mantle-Cell · Lupus Erythematosus, Systemic · Multiple Sclerosis, Chronic Progressive · Purpura, Thrombocytopenic, Idiopathic · Lymphoma, Large B-Cell, Diffuse, led by 2 companies.

Drug pageOrelabrutinib: every studyAll 95 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Oct 1, 202027 company-led studies, 13 open or runningLicense: InnoCare → Zenas BioPharma, Oct 2025Next primary completion: Aug 31, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
InnoCare Pharmaits history only2511 open or runningphase 3since Oct 1, 2020Jun 12, 2017Aug 31, 2028phase 3 · NCT06082102
Zenas BioPharma (USA)22 open or runningphase 3since Jul 3, 2025Jul 3, 2025Jun 2030phase 3 · NCT07299019

How these companies relate

From the companies’ own releases and filings, each linked; the registry does not say.

History and studies of Zenas BioPharma (USA) only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2019Named orelabrutinibINNProposed as its International Nonproprietary Name in WHO's List 122 · before, ICP-022
  2. Jul 3, 2025First study: phase 3 study in Multiple Sclerosis, Chronic ProgressiveFirst studyNCT07067463 · 705 planned · United States, Australia, Bulgaria and more
  3. Oct 8, 2025Zenas BioPharma licensed it from InnoCareLicenseMultiple sclerosis worldwide, and other uses outside cancer outside Greater China and Southeast Asia · announced · Zenas BioPharma and InnoCare (release)
  4. Dec 18, 2025Phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07299019 · 990 planned · United States, Australia, Belgium and more

Ahead

  1. Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07299019
  2. Jun 2030Primary completion: phase 3 study in Multiple Sclerosis, Chronic ProgressiveNCT07067463

TargetBeta

BTK →read by rule
“A small molecule inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase) ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 2 Zenas BioPharma (USA) leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07299019Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more3RecruitingJun 2030990
NCT07067463Multiple Sclerosis, Chronic Progressive · United States, Australia, Bulgaria and more3RecruitingJun 2030705

How it is read

Names in the registry

  • “ICP-022”, 11 entries
  • “Orelabrutinib”, 7 entries
  • “ICP-248+Orelabrutinib”, 3 entries
  • “Orelabrutinib High dose”, 1 entry
  • “Orelabrutinib Low dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.